About
We are proud to serve a purpose beyond ourselves.
Better outcomes for patients with unmet needs
The Abacus Medicine Group was founded in 2004 to improve access to critical medicines throughout Europe, driven by the vision of supporting better healthcare and outcomes for patients with unmet medical needs.
Abacus Medicine Pharma Services (AMPS) is the pharma services division of the Abacus Medicine Group and launched in 2014. We provide bespoke, end-to-end commercialisation solutions for global innovators who want to successfully launch their products in the European Union and United Kingdom.
The combination of AMPS’ industry experience with the market-leading operational capabilities of the Group provides our clients with a trusted framework for launching their innovative assets and achieving their commercial objectives.
Milestones
Sharing a common purpose
Abacus Medicine Pharma Services strives to create universal access to rare diseases medicines through impactful commercialisation solutions.
We aim:
- to empower our partners with bold and innovative commercialisation solutions.
- to strengthen key stakeholder relationships through transparent, engaging, and trusting collaboration.
- to advance patient well-being by ensuring swift and caring access to transformative treatments.
Leadership
Our experienced management team has extensive experience working for and with global pharmaceutical and biotech firms serving the rare disease community.
Flemming Wagner
Mr. Wagner is CEO and majority shareholder of Abacus Medicine. Prior to founding Abacus Medicine A/S in 2004, Mr. Wagner was the CEO of RAMCON A/S, a company focused on analytical and diagnostic equipment for hospitals and pharmaceutical industries.
Gary Kahn
A founding member of Abacus Medicine Pharma Services, Gary has been responsible for building the AMPS organisation and leading the charge on corporate development, business innovation, deal structuring, and strategic partnering with global biopharma firms.
Maxine Hamilton
Prior to joining AMPS in 2019, Maxine was Idis’ SVP of Managed Access Programs in Princeton, NJ and the Managing Director of Managed Access following its acquisition by Clinigen.
Marco Wulff
Prior to joining AMPS in 2020, Marco worked across the Abacus Medicine Group business heading up strategy and transformation projects.
Brett Wynn
Brett worked for the UK affiliate for Alliance Healthcare and Alcura, part of the former Walgreens Boots Alliance group, before joining AMPS in 2019.
Mark Ostle
Mark has 15 years’ experience within the Walgreens Boots Alliance group and is the former Head of Commercial at Alcura. He joined AMPS in 2019.
Alexander Iversen
Prior to joining AMPS in 2023, Alexander was Head of Corporate Strategy at Abacus Medicine Group, with deep experience within product management.
